by MM360 Staff | Nov 15, 2025 | Publications
Leuk Lymphoma. 2025 Oct;66(10):1767-1777. doi: 10.1080/10428194.2025.2513676. Epub 2025 Jun 3. ABSTRACT Eligibility for autologous transplantation is a key factor for tailoring treatment decisions in patients with newly-diagnosed multiple myeloma. For non-eligible...
by Marisa Wexler, MS | Nov 14, 2025 | Myeloma News
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as a potential tool for detecting early-stage pancreatic cancer. The CapsoCam system is similar to a large pill containing...
by MM360 Staff | Nov 14, 2025 | Uncategorized
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as a potential tool for detecting early-stage pancreatic cancer. The CapsoCam system is similar to a large pill containing...
by Margarida Maia, PhD | Nov 13, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend survival for people with malignant gliomas, the developer announced. Gliomas are a group of tumors that form...
by Marisa Wexler, MS | Nov 12, 2025 | Myeloma News
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data from a small clinical trial show. Results from the study were discussed earlier this...
